{"pub": "marketwatch", "url": "https://marketwatch.com/story/biogens-stock-rockets-after-earnings-beat-alzheimers-treatment-heads-for-regulatory-approval-process-2019-10-22?&mod=home-page", "downloaded_at": "2019-10-22 13:28:35.603131+00:00", "title": "Biogen's stock rockets after earnings beat, Alzheimer's treatment heads for regulatory approval process", "language": "en", "text": "Shares of Biogen Inc. BIIB, +1.57% rocketed 39% in very active premarket trading Tuesday, after the biotechnology company reported third-quarter profit and revenue that beat expectations and said it would pursue regulatory approval of its Alzheimer's treatment. Net income rose to $1.55 billion, or $8.39 a share, from $1.44 billion, or $7.15 a share, in the year-ago period. Excluding non-recurring items, adjusted EPS rose to $9.17 from $7.40 to beat the FactSet consensus of $8.28. Revenue grew 5% to $3.60 billion, above the FactSet consensus of $3.54 billion. Revenue for Tecfidera, Biogen's biggest seller, increased 3% to $1.12 billion to match expectations. Earlier, the company said a phase 3 trial of aducanumab, an investigational treatment for Alzheimer's, met its primary endpoint, and as a result, the company said it will pursue regulatory approval. The stock has lost 25.7% year to date through Monday, while the S&P 500 SPX, +0.69% has climbed 19.9%.", "description": "Shares of Biogen Inc. rocketed 39% in very active premarket trading Tuesday, after the biotechnology company reported third-quarter profit and revenue that...", "authors": ["Tomi Kilgore", "Reporter"], "top_image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "published_at": "2019-10-22"}